1. Stahl D, Gödel P, Balke-Want H, Gholamipoorfard R, Segbers P, Tetenborg L, Koker M, Dörr J, Gregor L, Bachurski D, Rose F, Simon AG, Good Z, Jakob J, Häupl B, Nill M, Flümann R, Riet T, Lange D, Blakemore SJ, Baurmann H, Voltin CA, Potter N, Schlözer L, Freihammer M, Wagener-Ryczek S, Iuga AI, Heger JM, Ludwig H, Schleifenbaum JK, Propp J, Bröckelmann PJ, Jachimowicz RD, Knittel G, Borchmann S, Merkelbach-Bruse S, Pallasch C, Peifer M, Rybniker J, Quaas A, Nitz M, Brägelmann J, Müller W, Persigehl T, Bozek K, Theobald SJ, Büttner R, Oellerich T, Hallek M, Kobold S, Chmielewski M, Reinhardt HC, Mackall C, Abedpour N, Borchmann P, Ullrich RT*. CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma Cancer Cell. (2025) Aug 11;43(8):1476-1494. *corresponding author |
| 2. George J, Maas L, Abedpour N, Cartolano M, Kaiser L, Fischer RN, Scheel AH, Weber JP, Hellmich M, Bosco G, Volz C, Mueller C, Dahmen I, John F, Alves CP, Werr L, Panse JP, Kirschner M, Engel-Riedel W, Jürgens J, Stoelben E, Brockmann M, Grau S, Sebastian M, Stratmann JA, Kern J, Hummel HD, Hegedüs B, Schuler M, Plönes T, Aigner C, Elter T, Toepelt K, Ko YD, Kurz S, Grohé C, Serke M, Höpker K, Hagmeyer L, Doerr F, Hekmath K, Strapatsas J, Kambartel KO, Chakupurakal G, Busch A, Bauernfeind FG, Griesinger F, Luers A, Dirks W, Wiewrodt R, Luecke A, Rodermann E, Diel A, Hagen V, Severin K, Ullrich RT, Reinhardt HC, Quaas A, Bogus M, Courts C, Nürnberg P, Becker K, Achter, V, Büttner R, Wolf J, Peifer M, Thomas RK. Evolutionary trajectories of small cell lung cancer under therapy. Nature. (2024) Mar;627(8005):880-889. http://dx.doi.org/10.1038/s41586-024-07177-7. |
3. Meder L*, Orschel CI, Bouchez CL, Gholamipoorfard R, Orschel CV, Stahl D, Kreer C, Koker M, Nill M, Kocak IG, Noh KW, Zhao X, Ullrich L, Häupl B, Jakob J, Eich ML, Florin A, Grüll H, Wolf J, Beleggia F, Büttner R, Oellerich T, Klein F, Brägelmann J, Reinhardt HC, Abedpour N, Ullrich RT.* ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer. Nat Commun. 2025 Dec 9;16(1):10983. doi: 10.1038/s41467-025-66800-x *corresponding author |
| 4. Borchmann S*, Selenz C, Lohmann M, Ludwig H, Gassa A, Brägelmann J, Lohneis P, Meder L, Mattlener J, Breid S, Nill M, Fassunke J, Wisdom AJ, Compes A, Gathof B, Alakus H, Kirsch D, Hekmat K, Büttner R, Reinhardt HC, Hallek M, Ullrich RT*. Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors. J Immunother Cancer. (2022) Oct;10(10):e004781. https://doi.org/10.1136/jitc-2022-004781. *corresponding author |
| 5. Volz C, Breid S, Selenz C, Zaplatina A, Golfmann K, Meder L, Dietlein F, Borchmann S, Chatterjee S, Siobal M, Schöttle J, … Ullrich, R.T. *. Inhibition of tumor VEGFR2 induces Serine 897 EphA2-dependent tumor cell invasion and metastasis in NSCLC. Cell Reports (2020) Apr 28;31(4):107568. https://doi.org/10.1016/j.celrep.2020.107568. *corresponding author |
| 6. Borchmann, S., Cirillo, M., Goergen, H., Meder, L., Sasse, S., Kreissl, S., Bröckelmann, P.J., von Tresckow, B., Fuchs, M., Ullrich, R.T. *, Engert, A. *. Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma. J Clin Oncol. (2019) 37, 3528–3537. https://doi.org/10.1200/jco.19.00985. *shared senior authorship |
| 7. Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Schlößer H, Odenthal M, Büttner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, and Ullrich RT*. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Res. (2018) Aug 1;78(15):4270-4281. https://doi.org/10.1158/0008-5472.can-17-2176. *corresponding author |
| 8. Chatterjee, S., Wieczorek, C., Schottle, J., Siobal, M., Hinze, Y., Franz, T., Florin, A., Adamczak, J., Heukamp, L., Neumaier, B., Ullrich, R. T. * Transient anti-angiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. Cancer Res. (2014) May 15;74(10):2816-24. https://doi.org/10.1158/0008-5472.can-13-2986. *corresponding author |
| 9. Chatterjee, S., Heukamp, L. C., Siobal, M., Schottle, J., Wieczorek, C., Peifer, M., Frasca, D., Koker, M., Konig, K., Meder, L., et al., … Ullrich, R.T.*. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest. (2013) Apr;123(4):1732-40. https://doi.org/10.1172/jci65385 *corresponding author |
| 10. Sos, M. L.*, Fischer, S.*, Ullrich, R. T.*, Peifer, M. *, Heuckmann, J. M., Koker, M., Heynck, S., Stuckrath, I., Weiss, J., Fischer, F., et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America (2008) 106, 18351-18356. https://doi.org/10.1073/pnas.0907325106. *equally contributed |
